It is our pleasure to invite you to participate in the Controversies in Thrombosis and Hemostasis Congress (CiTH) which will be held in Berlin, Germany on October 30-November 2, 2014 at the Maritime proArte Hotel.
CiTH is a ‘concept congress’ dealing mainly with controversial issues in the format of debates and discussions allowing ample time for speaker-participant interaction. Congresses are becoming more and more specialized and monothematic, allowing limited time to fully discuss clinical meaning and the line between Evidence Based Medicine (EBM) and working theories or ideas that are premature to implement into practice. CiTH addresses this need by facilitating effective debate on unresolved clinical and therapeutic dilemmas, supported by expert opinions resulting in agreement on timely issues.
The ability to discuss controversial topics with emphasis on clinical solutions in cases where no agreed-upon answers exist provides clinicians with an insight and a take-home message that ameliorates treatment in the most difficult situations.
What is CiTH?
- Academic gathering for physicians and scientists
- Devoted to clinical controversies
- Focused on debates and discussions
- Critical discussions on controversial issues
- Ample time for speaker-participant interaction
- Leading forum for opinion leaders, clinicians and industry
- Reaches best clinical recommendations & solutions for therapeutic dilemmas
Thrombotic disorders & antithrombotics
- Thrombophilia screen: Always /Never
- Role of thrombophilia in gestation complication: Major /Minor
- Heparins in the next 10 years: Extinguish /Prevail
- Warfarin in the next 10 years: Extinguish /Prevail
- Direct thrombin inhibitors and factor Xa inhibitors: Which one to choose for VTE treatment and prevention?
- Direct thrombin inhibitors and factor Xa inhibitors: Which one to choose for CAF?
- Should we monitor anti platelet therapy: Always /Never
- New antiplatelet agents: Ultimate solution /Limited application
- Pharmacogenomics: The ultimate tool /Useless and expensive
- The role of catheter guided thrombolysis in DVT: Routine practice /Not yet supported by evidence
- Extended VTE prophylaxis in medically ill patients: Yes /No
- Primary prevention of coronary heart disease by ASA: Yes /No
- Plasma derived vs. recombinant factor VIII concentrate: Which one to choose?
- The role of thrombopoietics in ITP: 1st line /3rd line /replacing splenectomy? Control of bleeding associated with new oral anticoagulants: Not an issue /Yet to be developed
- Replacement therapy before surgery of factor XI & factor VII deficient patient: No /When?
- Should infants with perinatal thrombosis be screened for thrombophilia and treated by antocoagulants?
- Is there a role for primary antocoagulants prolphylaxis in children with ALL?
- Prophylaxis for children with hemophilia should start early or after joint bleed? Is low dose regimen preferable to standard dose?
- Should we screen children for coagulopathies prior to surgery?
Serono Symposia International Foundation will submit the main congress program of the Controversies in Thrombosis and Hemostasis Congress (CiTH), Berlin, Germany, October 30-November 2, 2014, for accreditation by the European Accreditation Council for Continuing Medical Education (EACCME).
For the Italian participants
This program of the Controversies in Thrombosis and Hemostasis Congress (CiTH), Berlin, Germany, October 30-November 2, 2014, will be submitted for CME accreditation from the Italian Ministry of Health.
The CME accreditation is valid for the main congress program only and does not cover the company-sponsored symposia.
ISO 9001 Certification
Serono Symposia International Foundation has received the ISO 9001 Certification of Quality Management Systems. This Quality certification requires all participants to fill in a scientific questionnaire and to evaluate the overall quality of the event. Questionnaires will be distributed onsite during the congress.
CME for USA participants
UEMS/EACCME CME credit recognition – The American Medical Association (AMA) has an agreement of mutual recognition of continuing medical education (CME) credit with the European Union of Medical Specialties (UEMS). Under the terms of this agreement, the AMA will convert CME credit certified by the European Accreditation Council for Continuing Medical Education (EACCME), the accrediting arm of the UEMS, to AMA PRA Category 1 Credit™. Physicians (MDs, DOs or equivalent international degree) may have their EACCME credit converted to AMA PRA Category 1 Credit™ by applying to the AMA.